Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801302 | 0.80 | AKR1B1 (0.34) | MPIAKR1B1LMNAALDH1A1 | |
| SCHEMBL1735271 | 0.75 | AKR1B1 (0.37) | MPIAKR1B1 | |
| SCHEMBL6136752 | 0.75 | AKR1B1 (0.37) | MPIAKR1B1 | |
| SCHEMBL8891159 | 0.75 | AKR1B1 (0.37) | MPIAKR1B1 | |
| SCHEMBL3512416 | 0.75 | AKR1B1 (0.37) | MPIAKR1B1 | |
| SCHEMBL2323870 | 0.73 | AKR1B1 (0.36) | MPIAKR1B1 | |
| SCHEMBL2319489 | 0.73 | AKR1B1 (0.36) | MPIAKR1B1 | |
| SCHEMBL3357554 | 0.73 | AKR1B1 (0.36) | MPIAKR1B1 | |
| SCHEMBL2319597 | 0.73 | AKR1B1 (0.36) | MPIAKR1B1 | |
| Phosphoric Acid SCHEMBL10786308 | 0.73 | MPI (0.43) | MPIAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738591-A2 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-09-29 | — | — | US | claimed |
| US-9200026-B2 | Antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | claimed |
| EP-2772254-A2 | Novel Antibacterial Agents | Optimer Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| US-20130345410-A1 | NOVEL ANTIBACTERIAL AGENTS | OPTIMER PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-7601695-B2 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20060100164-A1 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | TETARD, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1638549-A2 | NOVEL ANTIBACTERIAL AGENTS | Optimer Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2004080391-A2 | NOVEL ANTIBACTERIAL AGENTS | OPTIMER PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | claimed |
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | disclosed |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | disclosed |
| CN-119661831-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119137271-A | Compositions and methods for capping RNA | 维乎医疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-7601695-B2 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | TETARD, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009055557-A1 | PROCESS FOR THE PREPARATION OF MACROLIDE ANTIBACTERIAL AGENTS | CEMPRA PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20060100164-A1 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | TETARD, INC. | 2006-05-11 | — | — | US | disclosed |
| EP-1638549-A2 | NOVEL ANTIBACTERIAL AGENTS | Optimer Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004080391-A2 | NOVEL ANTIBACTERIAL AGENTS | OPTIMER PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345410-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, CTSA, MRPL12 | MPI 1693/4885AKR1B1 4259/4885LMNA 2774/4885 |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | MPI 1969/4885AKR1B1 1283/4885LMNA 1942/4885 |
| US-20160280718-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | MPI 1105/4885AKR1B1 4172/4885LMNA 2956/4885 |
| US-20060100164-A1 | 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal | MLNR, RPL13A, PGC | MPI 180/4885AKR1B1 2777/4885LMNA 1871/4885 |
| US-20090209593-A1 | NOVEL ANTIBACTERIAL AGENTS | MRPL21, MRPL12, CTSA | MPI 1183/4885AKR1B1 4147/4885LMNA 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.